Main Web Site : www.henderson-morley.com

On line shop web site : http://www.herpesexpert.com (Frost and Simpson)

Investor Relations email : investors@henderson-morley.com

Henderson Morley is a drug discovery company

The company has been developed specifically to carry out preliminary sourcing and screening of candidates to combat diseases caused by the herpes family of viruses and certain other DNA viruses

Latest GECR update 15th October 2006

Latest GE&CR update - 15th Oct 2006 :


The news investors have all been waiting for - regarding negotiations with a US dermatological pharmaceutical firm has finally been unveiled. The licence has been granted under an agreement to
Cutanea, a U.S. pharmaceutical company, specialising in the development of dermatology products in the US market.

The licence is for new applications of ICVT for the treatment of dermatological conditions in humans. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence. Under the terms of the Agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

Under its business plan, Henderson Morley has stated its belief that, following clinical development and regulatory licence approval, sales of the product in excess of $1.5 billion could be achieved over the subsequent ten year period. This would give a potential royalty to Henderson Morley in excess of $115 million over this term.

As a drug discovery company, it is imperative that Henderson continues to grant licenses to further develop its technology portfolio. This is the group's third ICVT license agreement. Encouragingly, Cutanea has a great management team with a proven track record of commercialising dermatology products.

Meanwhile, the company has announced that it has been working away on a vaccine against Koi Carp Herpes virus. The group believes it is now ready to start field trials of a
candidate vaccine, in a collaboration with the Internationally renowned Hagerman
Aquaculture Research Institute in Idaho USA. The initial immunogenicity studies should produce results within 6 months, enabling Henderson Morley scientists to optimise the vaccine formulation, with a view to securing a product licence from the veterinary authorities as soon as practicable.

Clearly activity at Henderson Morley has been significant in recent weeks. The licensing announcement is very encouraging, but with the news now out of the way, the shares have eased - a classic case of buy on the rumour, sell on the news. That said, the stock has now pulled back below the recent placing price. With so much going on at the company, further newsflow in the shorter term is far from unlikely.

*Henderson Morley is a corporate client of Bishopsgate Communications which is owned by RSH, the ultimate owner of GE&CR.

Forecasts and a formal recommendation are suspended ahead of the publication of a detailed note next month.

That is no good reason to go out and buy them! ...... AVOID, though watch if you must

GE&CR
21st December 2006
The November Monthly View

Henderson Morley* has had a quiet month on the news front after the flurry of licensing activity over the autumn. Notably, the chairman and another director have since transferred 3.3 million shares to their SIPPs at a price of 1.64p. The two board members retain an interest in 26% of the company.

In September, Henderson announced a licensing agreement with US pharmaceuticals firm, Cutanea Life Sciences, for new applications of ICVT for the treatment of dermatalogical conditions. The agreement and takes the form of an exclusive American, Mexican and Canadian wide licence to bring products to market through a programme of pre-clinical and clinical development of treatments either by Cutanea or through a sub-licence.

Under the terms of the agreement, Henderson Morley will receive up to 6.675 million dollars in development and commercialisation milestone payments up to the point at which the application receives regulatory approval, and will receive royalties on net sales thereafter.

The group will now focus on working towards commercialisation of its patent portfolio in terms of both human and animal health, along with the development of ICVT. To this end it has secured funding of 1.2 million pounds through the issue of 60 million new shares.

Following clinical development and regulatory licence approval, sales in excess of 1.5 billion dollars of the ICVT product could be achieved over ten years. This would generate potential royalty revenues in excess of 115 million dollars for Henderson.

The shares have eased back further this month to 1.55p. With so much development going on at this drug discovery stock, further newsflow in the near term is far from unlikely. Buy

Henderson Morley up 46% today on heavy trading, anyone know why?
colombo.

No, not yet..... I picked this one up on the market scanner... bought in at 0.85p... doing ok on this one so far. I must read this thread to get to know what they actually do! I bet some good news is on the way, lets see

Cynic - On the 18th December you wrote about this company 'AVOID, though watch if you must' which sounds a bit like a retired schoolteacher who has spent a lifetime appearing knowledgeable to a bunch of 8 year olds.

What is it with you, why do you insist on posting negative stuff on a number of companies that you can't possibly have deep and detailed knowledge of?

I noticed you recently commented negatively on Party Gaming which subsequently rose by about a third, and now an almost 50% rise in the price of HM really tells us something meaningful about the quality of your investment advice.

Any other companies you hate at the moment?

Harry6
All the one's he hasn't got and some that he has.

Harry cynic i find is very balanced on his comments,each to their own with hml i guess if you bought @6p his comments would have been valid.

Sorry Capetown, utter nonsense.

On 18th December the price was 1.6 - cynic made his above quoted comment - it is now 2.2, up 45%. Backhand down the line I think.

But that isn't the point. The question I asked is why does he insist on posting negative stuff and warnings to everybody on loads of stocks that he doesn't hold!

Driver - I'll have a deal with you; the next time cynic posts a big downer on a stock, let's buy it? What do you say, anyone else in?

Harry6
I just did , bought in on the news.

HENDERSON MORLEY PLC
(AIM)

STATEMENT ON SHARE PRICE MOVEMENT

The Board of Henderson Morley plc ('Henderson Morley' or 'the Company'), notes
the movement in the Company's share price today.

The Company is able to confirm that it is in a late stage of negotiations with an
AIM-listed life sciences company. This proposed collaboration may lead to the
grant of a licence in respect of another project from Henderson Morley's product
portfolio. A further statement will be made in this respect at the appropriate
time.

The Company will be announcing its interim results for the six months to 31
October 2006 during the course of the next seven days.

--ENDS--

Harry6 i am celebrating the fact that for no reason other than a speculative one i bought 100 thou this am and i am very happy enjoy the ride

I wonder, perhaps Tepnel Life (TED )
2517

Up 103% on the day.

For god's sake Cynic, get out of that Pub/Tea-Dance/Darby & Joan Club and give us some more of your gloom. There's people on here not even millionaires yet!

*quickly scans board for more Cynic posts*

Harry6
Looking good for Monday there was only 20 minutes left of trading after the news came out, I bought in at 2.5. I want to double up or I will join Cynic and we will both be after you. LOL

Driver do you think its too late to top up at these prices?

Beware concerning buying at these levels. HML does have a habit of rising as a result of deals, but when the details come out and it is clear that money is a long way off then it falls like a stone. Look what happened in September last year.

Are you Cynic in disguise,

are you Cynic in disguise...

I agree with haystack.... be careful buying at these levels, only buy if you can sell immediately..... You might be able to make a bit more, just don't leave your computer screen....!

Whooosshhhhh

None of the deals have had up front money. The only money expected short/medium term is for product development. Real revenue is usually years away. It may be a good punt if you want to hang on to them for a few years. Short term the rise may have taken place already.

Haystack
I agree with half of what you are saying but who knows, may be the deals will keep coming?
This will definitely be marked up first thing on Monday and could go back to the 6p days.